FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Schwartz Carl I.
2. Issuer Name and Ticker or Trading Symbol

Predictive Oncology Inc. [ POAI ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
Chief Executive Officer
(Last)          (First)          (Middle)

3750 LAS VEGAS BLVD. SOUTH, APT. 4303
3. Date of Earliest Transaction (MM/DD/YYYY)

1/31/2020
(Street)

LAS VEGAS, NV 89158
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 1/31/2020  J(1)  50000 A (1)74430 (2)D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Third Amended and Restated Common Stock Purchase Warrant  (3)1/31/2020  J (1)    119442   (4)2/6/2024 Common Stock 119442  (1)0 D  

Explanation of Responses:
(1) Pursuant to an Exchange Agreement, between the Issuer and the Reporting Person, Dr. Schwartz delivered certain Notes and a Warrant to the Company to be cancelled and in exchange received: (a) a new promissory note issued by the Company with amended terms, and (b) a fee of $130,000, payable in the form of 50,000 shares of the Company's common stock, based on a closing bid price of $2.60 on January 30, 2020.
(2) Share ownership totals have been adjusted to reflect a 1 for 10 reverse stock split effected by the issuer on October 29, 2019.
(3) The Warrant covered 119,442 shares at exercise prices ranging from $7.04 to $11.88 per share.
(4) Currently exercisable.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Schwartz Carl I.
3750 LAS VEGAS BLVD. SOUTH
APT. 4303
LAS VEGAS, NV 89158
X
Chief Executive Officer

Signatures
/s/ Carl I. Schwartz, DDS2/4/2020
**Signature of Reporting PersonDate

Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Predictive Oncology Charts.
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Predictive Oncology Charts.